替西木单抗单用或联合奥拉帕利治疗复发性上皮性卵巢癌的临床研究
这项平行组研究将24例复发性上皮性卵巢癌患者随机分入替西木单抗单药组或联合奥拉帕利组,评估安全性、外周ICOS+ T细胞变化及最佳剂量组合。常见3级毒性为皮疹13%、免疫介导性肝炎8%、结肠炎8%,无4级及以上毒性及剂量限制性毒性。替西木单抗10 mg/kg/dose可诱导免疫激活,但未转化为临床缓解。
要点
- 替西木单抗10 mg/kg/dose联合奥拉帕利150 mg口服每日两次安全可行。
- 替西木单抗10 mg/kg/dose而非3 mg/kg/dose可诱导CD4+ICOS+和CD8+ICOS+ T细胞显著增加。
- 免疫激活未转化为临床缓解,仅1例部分缓解,无完全缓解。
核心结论
- 替西木单抗10 mg/kg/dose联合奥拉帕利150 mg口服每日两次安全可行。
- 替西木单抗10 mg/kg/dose而非3 mg/kg/dose可诱导免疫激活,但未转化为临床缓解。
研究设计与样本
- 平行组研究,纳入24例复发性上皮性卵巢癌患者,随机分入A组(替西木单抗单药10 mg/kg/dose静脉注射)或B组(剂量水平1:奥拉帕利口服150 mg每日两次联合替西木单抗静脉注射3 mg/kg/dose;剂量水平2:奥拉帕利口服150 mg每日两次联合替西木单抗静脉注射10 mg/kg/dose)。
- 入组标准包括可测量病灶和末次铂类治疗后进展<12个月。
- 主要目标为安全性、外周ICOS+ T细胞变化及最佳剂量组合的确定。
主要发现
- 24例患者中A组12例、B组剂量水平1共6例、B组剂量水平2共6例。
- 最常见的3级毒性为皮疹13%、免疫介导性肝炎8%、结肠炎8%;未发现4级及以上毒性;未发现剂量限制性毒性。
- 1例患者(B组剂量水平2)出现部分缓解;未观察到完全缓解。
- 10例患者最佳疗效为疾病稳定(A组7例、B组剂量水平2共2例、B组剂量水平1共1例)。
- 在替西木单抗静脉注射10 mg/kg/dose治疗组中,C1D15和C1D22时CD4+ICOS+和CD8+ICOS+ T细胞显著增加,而替西木单抗3 mg/kg/dose治疗组未出现显著增加。
关键数值与推荐
- 替西木单抗单药剂量为10 mg/kg/dose静脉注射。
- B组剂量水平1为奥拉帕利口服150 mg每日两次联合替西木单抗静脉注射3 mg/kg/dose。
- B组剂量水平2为奥拉帕利口服150 mg每日两次联合替西木单抗静脉注射10 mg/kg/dose。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: PARP inhibitors may work synergistically to improve the efficacy of immunotherapy in patients with epithelial ovarian cancer (EOC). We performed a parallel-arm study of tremelimumab, alone or with olaparib, in patients with recurrent EOC. METHODS: Eligibility criteria included measurable disease and progression <12 months from last platinum. Participants were randomized to Arm A (tremelimumab monotherapy, 10 mg/kg/dose intravenously [IV]) or Arm B (dose level 1 [DL1] olaparib orally 150 mg twice daily with tremelimumab IV 3 mg/kg/dose and DL2 olaparib orally 150 mg twice daily with tremelimumab IV 10 mg/kg/dose). Primary objectives were safety, change in peripheral ICOS+ T cells, and identification of optimal dose combination. RESULTS: Among 24 total patients (12 on Arm A, 6 on Arm B-DL1, 6 on Arm B-DL2), the most common grade 3 toxicities were rash (13 %), immune-mediated hepatitis (8 %), and colitis (8 %). No grade ≥ 4 toxicities were identified. No dose-limiting toxicities were identified. One patient (Arm B-DL2) experienced a partial response; no complete responses were observed. Ten patients (7 on Arm A, 2 on Arm B-DL2, and 1 on Arm B-DL1) had a best response of stable disease. There was a significant increase in CD4+ICOS+ and CD8+ICOS+ T cells at both C1D15 and C1D22 in groups treated with tremelimumab IV 10 mg/kg/dose, but not in those treated with tremelimumab 3 mg/kg/dose. CONCLUSIONS: Tremelimumab IV 10 mg/kg/dose with olaparib 150 mg orally twice daily was safe and feasible. Tremelimumab 10 mg/kg/dose (as opposed to 3 mg/kg/dose) was required for immune activation, although this did not translate into clinical responses.
引用
- Gaillard S, Verma N, Berg M, et al. A clinical study of tremelimumab, alone or in combination with olaparib, for recurrent epithelial ovarian cancer. Gynecol Oncol. 2025. PMID: 39951918. doi:10.1016/j.ygyno.2025.01.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。